Literature DB >> 15176995

Novel UBA domain mutations of SQSTM1 in Paget's disease of bone: genotype phenotype correlation, functional analysis, and structural consequences.

Lynne J Hocking1, Gavin J A Lucas, Anna Daroszewska, Tim Cundy, Geoff C Nicholson, Judit Donath, John P Walsh, Catriona Finlayson, James R Cavey, Barbara Ciani, Paul W Sheppard, Mark S Searle, Robert Layfield, Stuart H Ralston.   

Abstract

UNLABELLED: Three novel missense mutations of SQSTM1 were identified in familial PDB, all affecting the UBA domain. Functional and structural analysis showed that disease severity was related to the type of mutation but was unrelated to the polyubiquitin-binding properties of the mutant UBA domain peptides.
INTRODUCTION: Mutations affecting the ubiquitin-associated (UBA) domain of Sequestosome 1 (SQSTM1) gene have recently been identified as a common cause of familial Paget's disease of bone (PDB), but the mechanisms responsible are unclear. We identified three novel SQSTM1 mutations in PDB, conducted functional and structural analyses of all PDB-causing mutations, and studied the relationship between genotype and phenotype.
MATERIALS AND METHODS: Mutation screening of the SQSTM1 gene was conducted in 70 kindreds with familial PDB. We characterized the effect of the mutations on structure of the UBA domain by protein NMR, studied the effects of the mutant UBA domains on ubiquitin binding, and looked at genotype-phenotype correlations. RESULTS AND
CONCLUSIONS: Three novel missense mutations affecting the SQSTM1 UBA domain were identified, including a missense mutation at codon 411 (G411S), a missense mutation at codon 404 (M404V), and a missense mutation at codon 425 (G425R). We also identified a deletion leading to a premature stop codon at 394 (L394X). None of the mutations were found in controls. Structural analysis showed that M404V and G425R involved residues on the hydrophobic surface patch implicated in ubiquitin binding, and consistent with this, the G425R and M404V mutants abolished the ability of mutant UBA domains to bind polyubiquitin chains. In contrast, the G411S and P392L mutants bound polyubiquitin chains normally. Genotype-phenotype analysis showed that patients with truncating mutations had more extensive PDB than those with missense mutations (bones involved = 6.05 +/- 2.71 versus 3.45 +/- 2.46; p < 0.0001). This work confirms the importance of UBA domain mutations of SQSTM1 as a cause of PDB but shows that there is no correlation between the ubiquitin-binding properties of the different mutant UBA domains and disease occurrence or extent. This indicates that the mechanism of action most probably involves an interaction between SQSTM1 and a hitherto unidentified protein that modulates bone turnover.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15176995     DOI: 10.1359/JBMR.0403015

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  28 in total

1.  The majority of the genetic risk for Paget's disease of bone is explained by genetic variants close to the CSF1, OPTN, TM7SF4, and TNFRSF11A genes.

Authors:  Pui Yan Jenny Chung; Greet Beyens; Steven Boonen; Socrates Papapoulos; Piet Geusens; Marcel Karperien; Filip Vanhoenacker; Leon Verbruggen; Erik Fransen; Jan Van Offel; Stefan Goemaere; Hans-Georg Zmierczak; René Westhovens; Jean-Pierre Devogelaer; Wim Van Hul
Journal:  Hum Genet       Date:  2010-09-14       Impact factor: 4.132

Review 2.  Paget disease of bone.

Authors:  G David Roodman; Jolene J Windle
Journal:  J Clin Invest       Date:  2005-02       Impact factor: 14.808

3.  Paget's disease: epidemiology and pathophysiology.

Authors:  Margaret Seton
Journal:  Curr Osteoporos Rep       Date:  2008-12       Impact factor: 5.096

4.  p62 ubiquitin binding-associated domain mediated the receptor activator of nuclear factor-kappaB ligand-induced osteoclast formation: a new insight into the pathogenesis of Paget's disease of bone.

Authors:  Kirk H M Yip; Haotian Feng; Nathan J Pavlos; Ming H Zheng; Jiake Xu
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

Review 5.  Paget's Disease of Bone.

Authors:  Luigi Gennari; Domenico Rendina; Alberto Falchetti; Daniela Merlotti
Journal:  Calcif Tissue Int       Date:  2019-01-23       Impact factor: 4.333

6.  Neighbor of Brca1 gene (Nbr1) functions as a negative regulator of postnatal osteoblastic bone formation and p38 MAPK activity.

Authors:  Caroline A Whitehouse; Sarah Waters; Katie Marchbank; Alan Horner; Neil W A McGowan; Jelena V Jovanovic; Guilherme M Xavier; Takeshi G Kashima; Martyn T Cobourne; Gareth O Richards; Paul T Sharpe; Tim M Skerry; Agamemnon E Grigoriadis; Ellen Solomon
Journal:  Proc Natl Acad Sci U S A       Date:  2010-06-29       Impact factor: 11.205

7.  p62/sequestosome 1 deficiency accelerates osteoclastogenesis in vitro and leads to Paget's disease-like bone phenotypes in mice.

Authors:  Frank Zach; Franziska Polzer; Alexandra Mueller; André Gessner
Journal:  J Biol Chem       Date:  2018-03-19       Impact factor: 5.157

8.  SQSTM1/p62 regulates the expression of junctional proteins through epithelial-mesenchymal transition factors.

Authors:  Matthieu Bertrand; Valérie Petit; Ashish Jain; Raymonde Amsellem; Terje Johansen; Lionel Larue; Patrice Codogno; Isabelle Beau
Journal:  Cell Cycle       Date:  2015       Impact factor: 4.534

9.  Epidemiological, clinical, and genetic characteristics of Paget's disease of bone in a rural area of Calabria, Southern Italy.

Authors:  D Rendina; F Gianfrancesco; G De Filippo; D Merlotti; T Esposito; A Aloia; D Benvenuto; C L Vivona; G Annunziata; R Nuti; P Strazzullo; G Mossetti; L Gennari
Journal:  J Endocrinol Invest       Date:  2009-12-22       Impact factor: 4.256

10.  Somatic mutations in SQSTM1 detected in affected tissues from patients with sporadic Paget's disease of bone.

Authors:  Anand Merchant; Magda Smielewska; Nimit Patel; Jennifer D Akunowicz; Elizabeth A Saria; John D Delaney; Robin J Leach; Margaret Seton; Marc F Hansen
Journal:  J Bone Miner Res       Date:  2009-03       Impact factor: 6.741

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.